GlassScriptPhysician profile
Rubin Peter Gappy
NPI 1003825894
$1,140.85
in general payments reported to CMS, 2019-2025
13 companies · $226 in 2025
The $226 reported for 2025 was more than what 77% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37.19 · 2021: $39.66 · 2022: $420 · 2023: $121 · 2024: $297 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $643.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $360.00 | 2022 | |
| Pfizer INC. | $156.09 | 2019-2024 | |
| Cranial Technologies, INC | $125.11 | 2023-2025 | Doc Band |
| Collegium Pharmaceutical, INC. | $97.81 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $96.88 | 2023-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Ironshore Pharmaceuticals INC. | $79.56 | 2024 | |
| Supernus Pharmaceuticals, INC. | $68.93 | 2022-2025 | Qelbree |
| Sanofi Pasteur INC. | $41.33 | 2023 | |
| Tris Pharma INC | $32.68 | 2024-2025 | Dyanavel Xr |
| Kaleo, INC. | $26.72 | 2019-2023 | Auvi-Q |
| Alexion Pharmaceuticals, INC. | $21.57 | 2024 | Strensiq |
| Alk-Abello, INC | $17.17 | 2025 | Neffy, Odactra, Ragwitek |
| Seqirus USA INC | $17.00 | 2024 | Flucelvax |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rubin Gappy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.